While the upregulation of Bcl-2 and p53 in response to carboplatin and vinorelbine treatment may be beneficial for cancer cell survival and therapeutic responsiveness, it also elevates the risk of cardiotoxicity. This evidence concerns the gene TP53 and cancer.